HC Wainwright Reaffirms Buy Rating for BiomX (NYSEAMERICAN:PHGE)

BiomX (NYSEAMERICAN:PHGE)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $2.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 170.45% from the stock’s previous close.

BiomX Price Performance

PHGE stock opened at $0.74 on Wednesday. The company has a market cap of $13.44 million, a PE ratio of -0.23 and a beta of 1.31. BiomX has a 12-month low of $0.48 and a 12-month high of $8.55.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).